FDA panel members voted 17-0 to recommend the shot, with one abstention.


The endorsement by the agency’s Vaccines and Related Biological Products Advisory Committee will now be considered by the FDA, which could issue a final decision within days.


Next week, a CDC vaccine advisory group is expected to make its own recommendation. If it issues an endorsement and CDC Director Dr. Rochelle Walensky signs off, clotshots for young kids could begin immediately.


The Biden administration said it plans to distribute the doses as soon as it’s authorized by the FDA and CDC, which is expected to come early next month. The administration said it’s procured enough vaccine to inoculate all 28 million 5- to 11-year-olds in the U.S., and will distribute it in smaller dosing and with smaller needles to make it easier for pediatricians and pharmacists to administer to kids.


Children ages 5 to 11 account for roughly 9% of all reported Covid cases in the U.S., according to data presented to the committee by the FDA on Tuesday.


Still, some parents and advocacy groups argue Covid vaccinations for children are unnecessary as studies show kids are less likely to experience symptoms from the disease.


Some committee members said Tuesday that vaccinating younger groups would help the U.S. move toward Covid’s “endemic” phase, where the virus is still circulating but at lower levels than it is now. Others noted there are still unknowns, like the rate of myocarditis in young kids, but still emphasized the benefits of the shots outweighed the risks.


One member wondered whether they should issue a recommendation only for at-risk children.


“We don’t want children to be dying from Covid, even if it is far fewer children than adults and we don’t want them in the ICU,” member Dr. Amanda Cohn said before the vote. Prior to the vote, Dr. Peter Marks, the FDA’s top vaccine regulator, asked committee members to keep today’s debate “civil,” saying there were strong feelings on both sides.


“To be clear, today’s discussion is going to be about the scientific data that are presented, and it’s not about vaccine mandates which are left to other entities outside of FDA,” Marks said at the top of the meeting. “I ask that we keep our discourse today civil and focus on the science related to this issues so that we can get through a productive discussion.”


Pfizer asked the FDA to authorize its vaccine for kids ages 5 to 11 on Oct. 7. The company published data that showed a two-dose regimen of 10 micrograms — a third of the dosage used for teens and adults – is safe and generates a strong immune response in a clinical trial of young children.


It said the shots were well tolerated and produced an immune response and side effects comparable with those seen in a study of people ages 16 to 25.


Dr. Doran Fink, a deputy director of the FDA’s division of vaccines, said Tuesday a “small army” of FDA staff worked around the clock over the last month to ensure the data on kids they were presenting today was as accurate as possible.


The staff of the FDA published an analysis late Friday, saying a smaller dosage of the Pfizer vaccine appears to be safe and highly effective in young kids. They noted the increased risk of myocarditis and pericarditis but said the benefits of the shots, including preventing severe disease, hospitalization and death, would generally outweigh the risk of the rare inflammatory heart conditions.

No comments:

Post a Comment